3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Mesothelioma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Interventions
aldesleukin
43
Sunitinib
42
Cyclophosphamide
30
Nivolumab
29
pembrolizumab
27
Everolimus
27
Interferon-alpha
25
Bevacizumab
23
Sorafenib
22
Interleukin-2
20
fludarabine phosphate
19
Radiotherapy
18
Ipilimumab
18
Filgrastim
18
Axitinib
18
Gene Expression Profiling
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
Radiosurgery
13
fludarabine
11
Doxorubicin
11
Carboplatin
11
Blood Specimen Collection
11
temsirolimus
10
atezolizumab
9
Immunohistochemistry
9
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
CB-839
×
Genitourinary
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts